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Abstract
The expressions of different vascular endothelial growth factor (VEGF) isoforms are associated with the degree of tumor
invasiveness and the patient’s prognosis in human cancers. We hypothesized that different VEGF isoforms can exert
different effects on the functional and structural characteristics of tumor angiogenesis. We used dynamic contrast-enhanced
MRI (DCE-MRI) and steady-state contrast-enhanced MRI (SSCE-MRI) to evaluate in vivo vascular functions (e.g., perfusion and
permeability) and structural characteristics (e.g., vascular size and vessel density) of the tumor angiogenesis induced by
different VEGF isoforms (VEGF121, VEGF165, and VEGF189) in a murine xenograft model of human lung cancer. Tumors
overexpressing VEGF189 were larger than those overexpressing the other two VEGF isoforms. The Ktrans map obtained from
DCE-MRI revealed that the perfusion and permeability functions of tumor microvessels was highest in both the rim and core
regions of VEGF189-overexpressing tumors (p,0.001 for both tumor rim and core). The relative vessel density and relative
vessel size indexes derived from SSCE-MRI revealed that VEGF189-overexpressing tumors had the smallest (p,0.05) and the
most-dense (p,0.01) microvessels, which penetrated deeply from the tumor rim into the core, followed by the VEGF165-
overepxressing tumor, whose microvessels were located mainly in the tumor rim. The lowest-density microvessels were
found in the VEGF121-overexpressing tumor; these microvessels had a relatively large lumen and were found mainly in the
tumor rim. We conclude that among the three VEGF isoforms evaluated, VEGF189 induces the most densely sprouting and
smallest tumor microvessels with the highest in vivo perfusion and permeability functions. These characteristics of tumor
microvessels may contribute to the reported adverse effects of VEGF189 overexpression on tumor progression, metastasis,
and patient survival in several human cancers, including non-small cell lung cancer, and suggest that applying aggressive
therapy may be necessary in human cancers in which VEGF189 is overexpressed.
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Introduction
Angiogenesis is required for tumor growth and metastasis [1,2],
and it has been shown that high tumor angiogenesis activity is
associated with advanced tumor growth, distant metastases, and
an adverse prognosis in human cancers [3,4]. Vascular endothelial
growth factor (VEGF) is a potent angiogenesis factor under both
physiological and pathological conditions, and can induce tumor
angiogenesis [5,6]. The human VEGF gene (VEGF-A), which is
located on chromosome 6p, contains eight exons [7]. Alternative
splicing of the VEGF gene gives rise to multiple isoforms. Three
major VEGF-A isoforms (VEGF121, VEGF165, and VEGF189)
are expressed in a variety of human tissues and tumor specimens
[5,8], and have differential biochemical properties and biological
functions in physiological angiogenesis [9–13].
The biological functions of different VEGF-A isoforms in
pathological angiogenesis, such as tumor angiogenesis, are still
unclear. Several studies, including our previous study, have shown
that the expression of VEGF189 in a tumor is strongly associated
with a high tumor microvessel count, cancer metastasis, and short
patient survival in several human cancers [14–16], and with the
high xenotransplantability of several human cancer cells in mice
[17]. However, the mechanisms underlying these activities remain
unknown. Few studies have evaluated the roles of the different
major VEGF isoforms in determining the functions of the tumor
microvasculature and in facilitating tumorigenesis and tumor
metastasis via tumor angiogenesis.
Dynamic contrast-enhanced MRI (DCE-MRI) with the utiliza-
tion of T1 contrast medium Magnevist (Gd-DTPA, MW: 938
Dalton), is able to provide a vascular functional parameter, the
vascular transfer constant (Ktrans), which gives a measure of the
perfusion and permeability of vessels [18–21]. In addition, steady-
state contrast-enhanced MRI (SSCE-MRI) in combination with
T2 agent, Resovist (super paramagnetic iron oxide (SPIO)
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particles, size: 45–60 nm), can give structural information on
microvasculature, namely the relative vessel density index (rVDI)
and the relative vessel size index (rVSI) [22–26]. MRI is therefore
rapidly emerging as a promising method for assessing vascular
perfusion and permeability, and microvessel density (MVD) and
size in vivo in several human cancers [27–30].
We hypothesized that different VEGF isoforms can induce
tumor angiogenesis with different biological functions. Therefore,
we used DCE- and SSCE-MRI to evaluate the functional and
structural characteristics of tumor angiogenesis in lung cancers
overexpressing one of three different single VEGF isoforms
(VEGF121, VEGF165, or VEGF189) in a murine xenograft
model. The aim of this study was to test whether Ktrans, rVDI, and
rVSI of tumor angiogenesis differed among lung tumors
overexpressing one of three different VEGF isoforms. The results
will help to elucidate the role of different VEGF isoforms in
inducing tumor angiogenesis, the interaction between the structure
and function of tumor angiogenesis, and the mechanisms
underlying the association between the expression of a specific
VEGF isoform in a tumor and the patient’s clinical outcome in
human cancers.
Results
Generation of stable CL1-0 cell lines expressing different
VEGF isoforms
The parent lung cancer cell line CL1-0 was stably transfected
with VEGF121, VEGF165, or VEGF189 isoform cDNA or the
empty vector (mock transfected). About 20 clones of each VEGF-
isoform-expressing cell were analyzed, and one panel (i.e.,
VEGF121-3, VEGF165-C12, and VEGF189-A3) was ultimately
selected for experiments, as they showed similar levels of VEGF
isoform expression. The recombinant VEGF isoform mRNA
expressed by each clone was confirmed by real-time quantitative
RT-PCR. The recombinant protein expressed was also confirmed
by Western blotting (Fig. 1A), with the expected molecular weights
being 18 kDa (VEGF121), 23 kDa (VEGF165), and 26 kDa
(VEGF189). The amount of each VEGF isoform in the culture
supernatant, as determined by ELISA, was 1.14610222.96
102 ng/cell in a 48-h period. The VEGF isoforms expression
level in vivo in the implanted tumors determined by real-time
quantitative RT-PCR was similar among tumors overexpressing
one of three VEGF isoform (p= 0.953, one-way ANOVA)
(Fig. 1B).
Tumor volumes and growth curves of the VEGF-isoform-
overexpressing tumors, as measured by T2WI
The volumes of VEGF121-, VEGF165-, and VEGF189-
overexpressing tumors, as measured on T2-weighted images
(Fig. 2) increased from day 7 to day 35 after inoculation, whereas
mock tumors did not show any significant increase in tumor
volume (The mock tumor indicates the tumor derived from CL1-0
lung cancer cell line transfected with an empty vector). The tumor
growth curve showed that the VEGF189- and VEGF165-
overexpressing tumors grew faster than the others (n=6,
p,0.0001 by two-way ANOVA; all p values ,0.001 by Fisher’s
post hoc test; Fig. 3). The growth curve also showed that the
VEGF189- and VEGF165-overexpressing tumors grew rapidly
and exponentially after day 21 (p,0.05, by Fisher’s post hoc test;
Fig. 3).
At the end of day 35, the volumes of the tumor xenografts were
141.1622.4 mm3, 610.8687.8 mm3, and 738.06116.1 mm3 for
the VEGF121-, VEGF165-, and VEGF189-overexpressing tu-
mors, respectively, while that of the mock tumor xenograft was
37.467.9 mm3. The volumes of the VEGF165- and VEGF189-
overexpressing tumors on day 35 were significantly larger than
those of the mock-transfected and VEGF121-overexpressing
tumors (Fig. 3; all p,0.001 by Fisher’s post hoc test). The volume
of the VEGF189-overexpressing tumor tended to be larger than
that of the VEGF165-overexpressing tumor, but the difference did
not reach statistical significance.
Perfusion and permeability of tumor microvessels
evaluated by the Ktrans map on DCE-MRI
Figure 4A shows the temporal Ktrans map for the three VEGF-
isoform-overexpressing tumors from day 7 to day 35. Various
angiogenic patterns of Ktrans were observed in the different VEGF-
overexpressing and mock tumors. On day 35, the Ktrans signal was
observed mainly in the tumor rim in the mock-transfected and
VEGF121-overexpressing tumors, while in the VEGF165-overex-
pressing tumor, the Ktrans signal was located mainly in the rim,
with some in the core. A substantial amount of signal extending
from the rim to the core was noted in the VEGF189-
overexpressing tumor.
The temporal change in Ktrans values in the whole, rim, and core
of tumor increased significantly after day 14 in the VEGF189- and
VEGF165-overexpressing tumors, while there was no significant
increase in Ktrans values for the mock-transfected and VEGF121-
overexpressing tumors (Fig. 4B). The temporal Ktrans curves were
significantly higher in the VEGF189-overexpressing tumors in the
whole tumor (Fig. 4B, upper), tumor rim (Fig. 4B, middle), and
tumor core (Fig. 4B, lower) than in the others (all p,0.001 by
Fisher’s post hoc test).
On day 35, the Ktrans values at the rim and core of the tumors were
0.2560.07/min and 0.0660.03/min, respectively, for VEGF121-
overexpressing tumors, 0.5360.08/min and 0.2860.05/min for
VEGF165-overexpressing tumors, 0.8860.1/min and 0.6660.12/
min for VEGF189-overexpressing tumors, and 0.1960.05/min and
0.0660.02/min for mock tumor xenografts (Fig. 4C). Ktrans on day
35 was significantly higher in the VEGF189-overexpressing tumors
than in the other three types (all p,0.01 for the rim and p,0.001 for
the core by Fisher’s post hoc test; Fig. 4C, upper, middle). The core/
rim ratio of Ktrans in VEGF189-overexpressing tumors on day 35 was
0.7360.09, which was significantly higher than those in the
VEGF165- (0.5360.03) and VEGF121- (0.2660.08) overexpressing
tumors and in the mock tumor xenografts (0.2560.05; p,0.05,
p,0.0001, and p,0.0001, respectively, by Fisher’s post hoc test). This
indicates that the signal of the Ktrans map was distributed most deeply
from the rim to the core regions of the VEGF189-overexpressing
tumors (Fig. 4C, lower).
Vascular structural characteristics of tumor angiogenesis
assessed by the rVDI and rVSI on SSCE-MRI
Figure 5A and B show representative maps of rVDI and rVSI,
respectively, in the mock and different VEGF-overexpressing
tumors on day 36. The rVDI map shows only a few scattered
vessel density signals in the tumor rim in a mock-transfected
tumor. The VEGF189-overexpressing tumor shows a high
density of microvessels distributed from the rim to the core of
the tumor. In contrast, the VEGF121-overexpressing tumor
exhibits a low density of microvessels that is limited to the rim,
and the VEGF165-overexpressing tumor has a mixed low and
high density of microvessels that are distributed mainly in the
rim, with some in the core (Fig. 5A). As shown in the upper panel
of Fig. 5C, the rVDI of the whole tumor was highest in
VEGF189-overexpressing tumors (0.2660.03/s1/3), intermediate
in VEGF165-overexpressing tumors (0.1760.01/s1/3), and lowest
VEGF Isoforms Induced Angiogenesis Assessed by MRI
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in VEGF121-overexpressing (0.1160.01/s1/3) and mock-trans-
fected (0.0760.02/s1/3) tumors (all p,0.01 by Fisher’s post hoc
test). In both the rim and core, VEGF189-overexpressing tumors
exhibited the highest rVDI values among all VEGF-isoform-
overexpressing and mock-infected tumors (Fig. 5C, middle and
lower panels).
The rVSI map shows a few signals in the tumor rim in the mock
tumor. The rVSI map also indicates that the tumor microvessels
were almost all large vessels in the VEGF121-overexpressing
tumors (in the rim), mixed large and small in the VEGF165-
overexpressing tumors (mainly in the rim with some in the core),
and almost all small in the VEGF189-overexpressing tumors (from
the rim to the core; Fig. 5B).
As shown in the upper panel of Fig. 5D, the rVSI of the whole
tumor was highest in the VEGF121-overexpressing tumors
(37.2464.88), intermediate in the VEGF165-overexpressing
tumors (28.8461.46), and lowest in the VEGF189-overexpressing
(18.8262.27) and mock (9.8462.25) tumors (all p,0.05 by
Fisher’s post hoc test). In both the rim and core, the VEGF189-
overexpressing tumor had the lowest rVSI among the VEGF-
isoform-overexpressing tumors (Fig. 5D, middle and lower
panels).
Figure 1. Western blots of VEGF isoforms proteins expression in lung cancer cells and real-time quantitative RT-PCR of VEGF
isoform mRNA expression in tumor implants. A. Western blots of VEGF isoform protein expression in cell lysate of human CL1-0 lung cancer
cells transfected with single different VEGF isoform constructs. Each VEGF isoform protein comprised one glycosylated (upper) and one
unglycosylated (lower) protein. Tubulin was used as an internal control. B. Quantification of VEGF mRNA expression in vivo in the tumor implants by
real-time quantitative reverse transcription-PCR. The expression level of VEGF isoform was similar among CL1-0 lung cancer cell lines overexpressing
one of three VEGF isoforms (p = 0.953, one-way ANOVA).
doi:10.1371/journal.pone.0016062.g001
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Angiogenesis phenotype of tumors overexpressing
different VEGF isoforms by immunohistochemical
staining
At low power (Fig. 6A, 6100), the immunohistochemical
staining revealed a small number of microvessels distributed in
the periphery of the tumor nests of the mock tumors, and denser
tumor microvessels distributed mainly at the periphery of the
tumor or tumor nests in the VEGF121- and VEGF165-
overexpressing tumors. In the VEGF189-overexpressing tumors,
very dense microvessels were seen at both the rim and in the core.
At high power (Fig. 6A,6400, insert), VEGF121-overexpress-
ing tumors had more large microvessels with dilated lumens in
addition to the small-lumen microvessels, and VEGF165-overex-
pressing tumors had intermediate-sized microvessels. In contrast,
in the VEGF189-overexpressing and the mock-transfected tumors,
almost all of the microvessels had a small lumen.
MVD and number of large microvessels in tumor
xenografts on immunohistochemical staining
As shown in Fig. 6B, the MVD measured from immunohisto-
chemical staining of CD31 was highest in VEGF189-overexpress-
ing tumors (100.00613.30/mm2), intermediate in VEGF165-
overexpressing tumors (70.6666.84/mm2), and lowest in
VEGF121-overexpressing (40.07610.15/mm2) and mock-trans-
fected (29.9864.24/mm2) tumors (all p,0.05 by Fisher’s post hoc
test).
As shown in Fig. 6C, the number of vessels with a diameter
larger than 15 mm per tumor section in the tumor xenograft was
highest in VEGF121-overexpressing tumors (13.2160.95/mm2),
intermediate in VEGF165-overexpressing tumors (8.5861.11/
mm2), and lowest in VEGF189-overexpressing (5.5860.76/mm2)
and mock-transfected (3.2160.47/mm2) tumors (all p,0.05 by
Fisher’s post hoc test).
Discussion
Much remains to be elucidated about tumor-associated vascular
abnormalities; therefore, collecting more complete data regarding
changes in angiogenic microvascular structure and function can
facilitate the understanding of the mechanisms underlying tumor
angiogenesis and thus provide therapeutic implications. The Ktrans,
rVDI, and rVSI parameters obtained by DCE- and SSCE-MRI
are capable of providing data on vascular perfusion and
permeability, vessel density, and vessel size, respectively. To the
best of our knowledge, this is the first study to have used contrast-
enhanced MRI to evaluate the functional and structural
characteristics of tumor microvessels induced by different VEGF
isoforms in vivo, and to have correlated the functional and
structural characteristics of angiogenesis in VEGF-isoform-over-
expressing tumors.
Different VEGF isoforms reportedly exhibit different biochem-
ical properties. VEGF121 is a shorter, non-heparin-binding
acidic protein and is freely diffusible, whereas VEGF165 and
VEGF189 can bind heparin and heparan sulfate proteoglycans
(HSPGs) [13]. VEGF189 is frequently associated with the cell
surface and extracellular matrix, whereas VEGF165 is both a
secreted protein and is HSPG-associated [13]. VEGF165 and
VEGF189 each have different affinities for different coreceptors,
such as neuropilin-1 and neuropilin-2, and for HSPGs, such as
syndecan [14]. Recent studies have shown that different VEGF
isoforms can induce tumor angiogenesis exhibiting diffe-
rent morphological characteristics [31–34]. VEGF121- and
VEGF165-induced tumor microvessels were associated with
vasodilation, microvessel eruption, and hemorrhage [32]. In
contrast, VEGF189 can induce intense tumor angiogenesis
consisting of small, newly formed microvessels [31,33]. In this
study, our data from SSCE-MRI were consistent with these
morphological findings. We further demonstrated that different
VEGF isoforms can induce microvessels with different in vivo
vascular functions, and that VEGF189-induced angiogenesis in
lung cancers is characterized by the highest perfusion and
permeability characteristics. These results suggest that VEGF189
can induce the most-dense and smallest sprouting tumor
microvessels that have the highest perfusion and permeability
characteristics among the three VEGF-isoform-overexpressing
tumors examined.
Figure 2. Determining the core and rim regions of tumors on
T2WI for analyzing quantitative maps (Ktrans, rVSI, and rVDI).
doi:10.1371/journal.pone.0016062.g002
Figure 3. Growth curves of different VEGF isofrom overex-
pressing tumors and the mock tumors. Tumor growth of CL1-0
cancer cells overexpressing one of three VEGF isoforms at different time
points in SCID mice, estimated using T2WI. #, VEGF189 versus VEGF121
and the mock tumors; +, VEGF165 versus VEGF121 and the mock
tumors; *, comparison between different isoform-expressing and mock
tumors. Differences between VEGF-overexpressing tumors and mock
tumors were significant at the p,0.05 (one symbol), p,0.01 (two
symbols), p,0.001 (three symbols), and p,0.0001 (four symbols) levels.
doi:10.1371/journal.pone.0016062.g003
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The precise molecular and biological mechanisms underlying
the different morphological and functional characteristics of tumor
angiogenesis induced by different VEGF isoforms remain unclear;
further investigation is required to clarify this. Some recent
investigations have provided possible explanations for these
differences. Ruhrberg et al. showed that in the vegf188/188 mouse
brain, there was an increase in endothelial filopodia extensions,
which may lead to increased vascular branching and sprouting
angiogenesis [35]. In contrast, VEGF121 was shown to lack the
ability to induce sprouting angiogenesis [35], but only coopts
preexisting peritumor vessels and induces vasodilation. Our MRI
data provide solid evidence of the biological behavioral differences
Figure 4. The temporal Ktrans maps and values of different VEGF isofrom overexpressing tumors and the mock tumors. In vivo
temporal Ktrans map and quantitative curve for tumor xenografts of CL1-0 cancer cells overexpressing one of three VEGF isoforms at different time
points, evaluated by DCE-MRI. (A) Representative Ktrans color map in the different VEGF-overexpressing and mock-transfected tumors (within dotted
circle) at different times, from day 7 to day 35 postimplantation. The color ranged from blue (0/min, lowest Ktrans) to red (0.8/min, highest Ktrans). B)
Quantitative analysis of Ktrans values over time in the regions of the whole tumor (upper), tumor rim (middle), and tumor core (lower). #, VEGF189
versus other isoforms and the mock tumors; +, VEGF165 versus VEGF121 and mock tumors. Differences between VEGF-overexpressing tumors and
mock tumors were significant at the p,0.05 (one symbol), p,0.01 (two symbols), p,0.001 (three symbols), and p,0.0001 (four symbols) levels. (C)
Ktrans values on day 35 in the tumor rim (upper) and tumor core (middle), and the ratio of Ktrans values between the tumor core and tumor rim (lower).
Differences between VEGF-overexpressing tumors and mock tumors were significant at the *p,0.05, **p,0.01, ***p,0.001, and ****p,0.0001 levels.
doi:10.1371/journal.pone.0016062.g004
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of endothelial cells stimulated by different VEGF isoforms in vivo in
tumor angiogenesis. There is also evidence that the molecular
signaling differs among these isoforms. VEGF165 and VEGF189
can bind to VEGF coreceptors, such as neuropilin-1 and HSPGs,
and these bindings can modify VEGF signaling in endothelial cells,
controlling the bioavailability of VEGF to VEGF receptors [36–
38]. The activities of VEGF189 in nuclear translocation [34] and
crosstalk of VEGF-signaling pathways with integrins [39] may also
affect the biological functions of different VEGF isoforms in tumor
angiogenesis. The differential cell biological functions and
molecular signal transductions also translate to the different in
vivo morphological and functional characteristics of tumor
angiogenesis induced by different VEGF isoforms in human
cancers.
Figure 5. The rVDI and rVSI maps and values of different VEGF isofrom overexpressing tumors and the mock tumors. In vivo rVDI and
rVSI maps and quantitative curves for tumor xenografts of CL1-0 cancer cells overexpressing one of three VEGF isoforms, evaluated by SSCE-MRI.
Representative high-resolution maps of the (A) rVDI and (B) rVSI in the different VEGF-overexpressing and mock tumors on day 36 after tumor
implantation. In rVDI map, the color ranged from blue (0 S-1/3, lowest rVDI) to red (0.4 S-1/3, highest rVDI). In rVSI map, the color ranged from blue (0,
lowest rVSI) to red (30, highest rVSI).Quantitative analysis of (C) rVDI and (D) rVSI in the whole tumor (upper), tumor rim (middle), or tumor core
(lower). Differences between VEGF-overexpressing tumors and mock tumors were significant at the *p,0.05, **p,0.01, ***p,0.001, and
****p,0.0001 levels.
doi:10.1371/journal.pone.0016062.g005
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Ktrans mapping revealed that the Ktrans of the microvessels were
highest in VEGF189-overexpressing tumors. The high Ktrans value
of VEGF189-overexpressing tumors may be attributable to the
highest density of microvessels that penetrate deeply from the rim to
the core of the tumor, which can provide a high vascular perfusion
function. Previous studies showed that VEGF189 can enhance the
vascular permeability of skin vessels and proliferating intratumoral
vessels, as assessed by Mile’s vascular permeability assay and Ig G
staining [13,31]. Our data are consistent with these findings, and
suggest that the increasing permeability may contribute to the
highest Ktrans value observed in VEGF189-overexpressing tumors.
In addition, our previous report has shown that the blood flow (Fr),
microvessel permeability (PSr) and the blood volume (Vb)
determined by DCE-MRI were all significantly increased in tumor
overexpressing VEGF 189 isoform [40]. Tozer et al. recently showed
that mouse VEGF188 can induce narrow microvessels with the
greatest microvessel length, resistance to hemorrhage and resistance
to antiangiogenesis agent therapy, but is associated with tumor
vascular maturity [34]. This may arise from different cell lines to be
used to overexpress VEGF isoform (fibrosarcoma cell line vs lung
adenocarcinoma cell line), different method of experiment and
different model used. However, both studies showed the different
VEGF isoform has different function and this may determine the
different characteristics of microvessels in tumors in different
organs. Although VEGF121-overexpressing tumors have larger
microvessel diameters, as shown by the high rVSI, the correspond-
ing Ktrans value is low. This may indicate that Ktrans is dependent
mainly on the rVDI rather than the rVSI. The precise relationship
between Ktrans and rVSI or rVDI may be difficult to determine due
to the complicated tumor microenvironmental physiology with
overexpression of different VEGF isoforms. Nevertheless, Ktrans has
been shown previously to be associated with vessel density. Previous
data had also shown that stasis of blood will occur in the dilated and
tortuous vascular spaces.
Figure 6. The immunohistochemical staining of microvessels of different VEGF isofrom overexpressing tumors and the mock
tumors. Angiogenesis phenotypes of microvessels evaluated by immunohistochemical staining of tumor xenografts overexpressing different VEGF
isoforms. (A) Immunohistochemical staining of tumor microvessels (brown color,6100 in main panel,6400 in the inset) in tumor xenografts. (B) The
microvessel density was highest in the VEGF189-overexpressing tumors, intermediate in the VEGF165-overexpressing tumors, and lowest in the
VEGF121-overexpressing tumors. (C) The number of vessels with a diameter larger than 15 mm per tumor section in the tumor xenograft was highest
in the VEGF121-overexpressing tumors, intermediate in the VEGF165-overexpressing tumors, and lowest in the VEGF189-overexpressing tumors.
Differences between VEGF-overexpressing and mock tumors were significant at the *p,0.05, **p,0.01, ***p,0.001, and ****p,0.0001 levels.
doi:10.1371/journal.pone.0016062.g006
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Because VEGF121 is a shortest, non-heparin-binding acidic
protein which is freely diffusible, they will be secreted from cell to
the outside environment once they are synthesized. The amount of
VEGF121 protein remained in cell is supposed to be lower as
compared to other VEGF isoforms which have higher proportion
of VEGF proteins remaining in the cells. Therefore, the density of
VEGF121 protein band in Western blot obtained from cell lysate
of CL1-0 cancer cells can not stand for the total amount of
VEGF121 proteins synthesized or the amount that are secreted to
the environment. We have quantitated the amount of VEGF
isoforms that are secreted out of cell into the supernatant by
ELISA, and the results showed that the amount of VEGF121
protein in the supernatant was similar to the amount of the other
two VEGF isoforms. In addition, we further quantitated the
VEGF expression level in vivo in the tumor implants resected from
SCID mice using real-time quantitative RT-PCR, and the result
showed the expression level of VEGF isoform was similar among
tumors from CL1-0 lung cancer cell lines overexpressing one of
three VEGF isoforms (p = 0.953, one-way ANOVA)(Fig. 1B).
Therefore, the differences in tumor growth and angiogenic
properties between VEGF isoforms in this study are because of
different function of VEGF isoforms, in stead of resulting from the
different expression level of VEGF between different VEGF
isoforms in tumors.
In our study, the VEGF189-induced angiogenesis had the
highest MVD, penetrated deeply from the tumor rim to the tumor
core, and had the highest perfusion and permeability functions
among three different VEGF-isoform-overexpressing tumor types.
However, the tumor size did not differ significantly between
VEGF165- and VEGF189-overepxressing tumors. We observed
the viability of the tumors using immunohistochemistry and
hematoxylin-eosin staining, and we found that the central necrosis
is greater for VEGF165-overexpressing tumors than for
VEGF189-overexpressing tumors. This indicates that despite
having similar total tumor volumes, the viable part of the tumor
is larger in VEGF189- than in VEGF165-overexpressing tumors.
This also implies that VEGF189-induced microvessels function
better than VEGF165-induced microvessels in maintaining the
viability of tumors.
Clinically, an association has been found between the
expression of different VEGF isoforms in human tumors and
different clinicopathological characteristics and patient outcome.
Tokunaga et al. [14,41] demonstrated that in colon cancer
patients, tumors with VEGF189 mRNA expression have a higher
incidence of liver metastasis, higher involvement of the veins, and
are associated with a poorer patient prognosis than those lacking
VEGF189 mRNA expression. In our own study [15] and others
[14-16,41,42], a high tumor expression of VEGF189 was
significantly correlated with large tumors, advanced clinical stage,
and systemic metastasis, and was an independent prognosis factor
in colorectal, renal cell, and non-small-cell lung cancers. In
addition, Tokunaga et al. [17] showed that VEGF189 expression is
associated with the increased xenotransplantability of human
esophageal cancer in the skin of mice. In the present study, the
DCE-MRI revealed a high perfusion and permeability function of
the tumor microvessels, and SSCE-MRI revealed a very high
density of small microvessels penetrating from the tumor rim to the
core in VEGF189-overexpressing tumors. These characteristics of
tumor angiogenesis may provide a good supply of nutrients and
O2 for tumor growth, and the highly permeable, dense
microvessels may facilitate cancer cell metastasis. These specific
functional and structural characteristics of VEGF189-induced
tumor angiogenesis may contribute to the reported increased
tumorigenesis, high incidence of systemic metastasis, and adverse
prognosis of patients and the high xenotransplantability of human
cancers that overexpress VEGF189 [14–17,41,42].
One traditional method used to evaluate tumor angiogenesis is a
histological technique called MVD counting in sections of tumor
specimens. However, MVD measurements can vary within the
tumor, and this may allow sampling bias to produce misevalua-
tions of angiogenesis. Currently, the biomedical imaging modal-
ities that have been used in evaluating tumor angiogenesis include
MRI, positron emission tomography, ultrasound, optical imaging,
and computed tomography [30,43–45]. Among these, MRI has
the advantage of being noninvasive, nonradioactive, rapid, and
having a high resolution. Our study showed that DCE-MRI is a
good method for evaluating the perfusion and permeability
functions of tumor microvasculature and that SSCE-MRI is a
highly sensitive method for measuring vessel density and size. In
this study, DCE- and SSCE-MRI provided a noninvasive and
high-resolution imaging method for the evaluation of function and
vessel density of tumor angiogenesis in vivo and can be performed
repeatedly to assess the progress of tumor angiogenesis, and can
provide information about the temporal vascular function and
spatial distribution of microvessels. These unique characteristics
make DCE- and SSCE-MRI useful for assessing tumor angiogen-
esis before, during, and after anticancer and antiangiogenesis
therapies.
We conclude that different VEGF isoforms can induce tumor
angiogenesis with different functional and structural characteris-
tics, as demonstrated by DCE- and SSCE-MRI, in non-small-cell
lung cancers. VEGF189 can induce the most-dense, small,
sprouting microvessels that penetrated deeply from the tumor
rim to its core, and has the highest microvessel perfusion and
permeability functions. These microvessel characteristics in
VEGF189-overexpressing tumors may contribute to the reported
adverse effects of VEGF189 overexpression on tumorigenesis,
systemic metastasis, and patient survival in several human
malignancies, including non-small-cell lung cancer. The finding
of high MVD and high perfusion function in VEGF189-induced
angiogenesis also has valuable therapeutic implications, suggesting
the necessity of aggressive treatment of VEGF189-overexpressing
lung cancers.
Materials and Methods
Cell lines
A series of model cell lines of a human lung adenocarcinoma
(i.e., CL1-0, CL1-1, CL1-5, and CL1-5-F4) with increasing
invasiveness and metastatic capabilities was established previously
[46,47]. The CL1-0 cell line, which has low capacities for both
tumorigenesis and metastasis and minimal endogenous VEGF
production, was chosen for this study.
Construction of the VEGF isoform expression vector and
stable transfection
The full-length cDNA sequence for human VEGF was obtained
from a National Center for Biotechnology Information nucleo-
tide sequence search (GenBank E14233, Accession no. NM_
001025366). The forward primer, 59-CGC GGA TCC GAA ACC
ATG AAC TTT CTG CTG TCT T-39 with a BamH1 restriction
site, and the reverse primer, 59-GCT CTA GAC CCG GCT CAC
CGC CTC GGC TT-39 with an Xbal restriction site, were
designed, and the PCR products of the VEGF isoforms from
normal lung tissue mRNA were purified and verified in sequence,
and were used to transfect competent cells.
The cDNA for VEGF121, VEGF165, or VEGF189 was cloned
into the constitutive mammalian expression vector pTR2 (BD,
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Franklin Lakes, NJ, USA) to yield the pTR2-‘‘VEGF isoform
constructs’’. CL1-0 cells were transfected with the pTR2-VEGF
isoform constructs using the Lipofectamine 2000 reagent (Invitro-
gen, Carlsbad, CA, USA).
VEGF isoform mRNA and protein expression
The expression of VEGF isoform proteins by CL1-0 cells
transfected with the pTR2-VEGF isoform constructs was
confirmed by Western blot analysis using rabbit polyclonal anti-
human-VEGF as a primary antibody (1:2000 dilution; Upstate
Biotechnology, Waltham, MA, USA), as described previously [13].
VEGF isoform mRNA in the transfected CL1-0 cells or protein in
the supernatant was also measured by a real-time quantitative RT-
PCR assay (ABI, Carlsbad, CA, USA) [48] and ELISA assay
(R&D, Minneapolis, MN, USA), respectively [13].
In vivo tumorigenesis assay in a murine xenograft model
Twenty-four male, 6-week-old severe combined immunodefi-
ciency (SCID) mice from the Laboratory Animal Center, National
Taiwan University College of Medicine were used for experi-
ments. For tumor growth in animals, 46106 control cells (mock) or
individual VEGF-isoform-transfected CL1-0 cells in a volume of
0.2 mL were injected subcutaneously into the right dorsal region
of each animal, and the mice were examined every 7days (from
week 1 to week 5) for tumor appearance by MRI. After 36 days,
the animals were sacrificed and the tumors were confirmed by
histological examination. The tumor tissue was embedded in OTC
medium and frozen at –80uC, and then three consecutive sections
were cut from each OTC block for immunohistochemical staining
for CD31. The experiments were performed on four groups of six
mice each for CL1-0 cells transfected with different VEGF
isoforms or mock transfected. The animal experiments were
approved by the Laboratory Animal Center, National Taiwan
University College of Medicine.
MRI of the tumor xenografts in SCID mice
All MRI experiments were performed on a horizontal 7.0-T
Pharmascan 70/16 spectrometer, and T2-weighted imaging
(T2WI) and DCE-MRI were performed on days 7, 14, 21, 28,
and 35 after tumor implantation. The mice were initially
anesthetized with 5% isoflurane at 5 L/min O2. When fully
anesthetized, the animal was placed in a prone position and fitted
with a custom-designed body holder inside the magnet. Isoflurane
was then maintained at 0.5–1.5% at 1 L/min O2 throughout the
experiments. To maintain body temperature at 37uC, warm air
was pumped through the bore of the magnet. Images were
acquired using a 38-mm volume coil as both the transmitter and
receiver coil. Contrast medium was injected via orbital veins for
acquiring DCE- and SSCE-MRI data.
1. Tumor volume measurement. The tumor region was
identified from body tissues using T2WI. Multislices of T2WI were
acquired by spin-echo sequencing with a repetition time (TR) of
5000 ms, an echo time (TE) of 70 ms, a field of view (FOV) of
3 cm, a number of excitations (NEX) of 2, a matrix size of
2566128 (zero filled to 2566256), and a slice thickness (Slth) of
0.5 mm with no interslice gap so that the entire tumor was
covered. The outline of the tumor was delineated by the operator
based on the good contrast provided by T2WI between the body
tissue and the tumor area. Once the whole tumor region was
identified, the total tumor volume was calculated by summing the
tumor area in three dimensions using Avizo software (TGS, San
Diego, CA, USA).
2. DCE-MRI. The perfusion and permeability functions of
tumor angiogenesis were assessed using the Ktrans map obtained
from DCE-MRI using a T1-weighted spin-echo sequence. Spin
echo sequence was used because it’s insensitive to signal loss and
susceptibility artifact in heterogeneous tumor tissue and blood
leak; it also provides a better signal-to-noise ratio to increase
accurate data fitting [49]. The images were acquired with TR, TE,
FOV, Slth, NEX, and matrix-size values of 400 ms, 10 ms, 3 cm,
1.5 mm, 1, and 256664 (zero filled to 2566256), respectively. A
series of 40 axial T1-weighted images were acquired before,
during, and after an injection of Gd-DTPA (Magnevist, MW: 938
Dolton, Schering, Berlin, Germany) at a dose of 0.2 mmol/kg.
Precontrast T1-weighted maps were acquired by inversion-
recovery fast imaging with a steady-state precession sequence,
with TR, TE, FOV, Slth, NEX, flip angle, and matrix-size values
of 4 ms, 1.8 ms, 3 cm, 1.5 mm, 1, 60u, and 1286128, respectively,
and 18 inversion times, ranging from 62 to 2510 ms with an
increased interval of 144 ms. The Ktrans maps were evaluated on
days 7, 14, 21, 28, and 35 after tumor implantation.
3. SSCE-MRI. Transverse relaxation rates (DR2 and DR2*),
obtained by SSCE-MRI, were used to determine the structural
properties of the tumor vasculature on day 36 after tumor
implantation. DR2 and DR2* were determined by performing
T2WI and T2*-weighted imaging (T2*WI), respectively, before
and after an injection of iron oxide (Resovist, particle size ranged
from 45–60 nm, Schering) at a dose of 10 mg/kg. The
postcontrast image acquisition was delayed by 5 min to ensure a
steady-state distribution of the contrast agent in the vascular
network. The O2 gas for pumping vaporized isoflurane was used
to raise the DR2* contrast in veins and venules due to the
deoxyhemoglobin within the vessels minimized the difference
between precontrast and postcontrast T2*WI. T2WI and T2*WI
were performed in the same location with FOV, Slth, NEX, and
matrix-size values of 3 cm, 1.5 mm, 2, and 2566128 (zero filled to
2566256), respectively. T2WI was conducted using a fast spin-
echo sequence with a TR of 5000 ms, a pseudoecho time of
70 ms, and an echo-train length of 8, while T2*WI was conducted
using a fast low-angle shot sequence (FLASH) with a TR of
700 ms, a TE of 10 ms, and a flip angle (FA) of 15u. In FLASH
sequence, the contrast depends on the selected parameters of TR,
TE, and FA. The FA of 15u with TR of 700 ms was set to reduce
T1 weighting on the images, while 10 ms for TE was found to
enhance T2* contrast with no susceptibility artifact.
4. Data analysis. In DCE-MRI, the kinetic analysis of
dynamic signal enhancement by Gd-DTPA was based on the
compartment model of Tofts [20,21]. The change in the image
intensity of DCE-MRI in the tissue was due to leakage of the
contrast agent into the tissue from the blood vessel. The rate of
contrast agent uptake (dCt(t)/dt) can be given as dCt(t)/dt = Ktrans
6 (Cp–Ct/ve), where K
trans is vascular permeability, Cp is the
concentration of contrast agent in the plasma space, Ct is the
concentration of contrast agent in the tissue extravascular and
extracellular space, and ve is the leakage space per unit volume of
measured tissue. Optimal values of the pharmacokinetic
parameters Ktrans and ve for each pixel were calculated by fitting
the enhanced curve of the tissue signal using nonlinear regression
analysis. In SSCE-MRI, the transverse relaxation rate shifts are
given by DR2 = ln(Spre/Spost)/TE and DR2
* = ln(Spre
*/Spost
*)/
TE, where Spre, Spost and Spre
*, Spost
* are the precontrast and
postcontrast signal intensities for the spin echo and gradient echo,
respectively. The rVDI and rVSI are derived from the relaxation
rate shift ratio as DR2/(DR2*)
2/3 and DR2*/DR2, respectively [22–
26]. All of the parametric maps (Ktrans, rVSI, and rVDI) were
analyzed in the regions of the tumor core and rim, which were
delineated by T2WI. The region of the tumor core was defined as
50% of the distance from the central point of tumor to its outside
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boundary, while the region of tumor rim was determined by the
subtraction of the area of the tumor core from that of the total
tumor area (Fig. 2). The processing software for all of the
quantitative analyses of the data obtained by DCE- and SSCE-
MRI was written in MATLAB (MathWorks, Natick, MA, USA).
Assessment of phenotypes of tumor angiogenesis and
microvessel counts by immunohistochemical staining
The resected tumor specimens were embedded in OTC
medium and frozen at –80uC. Sections (5 mm) were then prepared
and stained for 60 min at room temperature with rat monoclonal
anti-mouse CD31 antibody (1:20 dilution; PharMingen, San
Diego, CA, USA) to stain endothelial cells. The sections were
washed and then incubated for 30 min at room temperature with
rabbit anti-rat Ig antibody (Zymed Laboratories, South San
Francisco, CA, USA), and then for a further 30 min at room
temperature with a 1:20 dilution of avidin-biotin peroxidase
complex (Zymed Laboratories). The color was developed by
incubating the slides for 20 min with 3,3-diaminobenzidine
(Zymed Laboratories). Counterstaining was performed using
Mayer’s solution, giving a blue background. The capillaries
surrounding the alveoli of normal mouse lung tissue were used
as the positive control for anti-CD31 antibody staining. Negative
controls were sections stained without the use of primary
antibodies or using a control IgG instead of primary antibodies.
The density and size of the vasculature were analyzed in digital
images using the Metamorph imaging processing package
(Universal Imaging Corporation, West Chester, PA, USA).
Statistical analysis
All statistical tests were performed using StatView software
(version 5.0.1, SAS Institute, Cary, NC, USA). Comparison of
variables (temporal changes in tumor volume and Ktrans) among
tumors overexpressing different VEGF isoforms and the mock-
transfected cells was performed using two-way ANOVA analysis
followed by Fisher’s post hoc test for pair comparisons. One-way
ANOVA analysis followed by Fisher’s post hoc test for pair
comparisons was used to investigate the effects of different VEGF
isoforms on rVDI, rVSI, MVD, and microvessel size. Data are
presented as mean6SD values, and the level of statistical sig-
nificance was set at p,0.05.
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